| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 14 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 890.4K | $40.16M | - | |
| CEO | 875.0K | $39.46M | - | |
| Other | 740.2K | $33.38M | - | |
| 10% | 245.7K | $11.08M | -281,408 | |
| COO | 215.0K | $9.70M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 4,250 | $22.23 | $94,474.41 | -100% | -12.1% | -30.5% | |
| Nov 27, 2024 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 5,250 | $24.89 | $130,688.38 | -84.0% | -20.8% | -15.0% | |
| Oct 28, 2024 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 6,250 | $28.56 | $178,484.63 | -90.6% | -25.7% | -24.8% | |
| Oct 18, 2024 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 814 | $30.00 | $24,422.44 | -100% | -24.2% | -26.2% | |
| Oct 18, 2024 | Patel Anish54 | Chief Operating Officer | Sell | 716 | $30.00 | $21,482.51 | -0.2% | -24.2% | -26.2% | |
| Oct 18, 2024 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sell | 847 | $30.00 | $25,412.54 | - | -24.2% | -26.2% | |
| Oct 18, 2024 | Kintz Samuel51 | President And CEO | Sell | 924 | $30.00 | $27,722.68 | - | -24.2% | -26.2% | |
| Oct 18, 2024 | Collins Helen Louise63 | Chief Medical Officer | Sale+OE | 816 | $30.00 | $24,482.45 | -100% | -24.2% | -26.2% | |
| Oct 18, 2024 | Heyman Richard A.74 | Director | Sell | 1,570 | $30.00 | $47,104.03 | -1.0% | -24.2% | -26.2% | |
| Oct 15, 2024 | Heyman Richard A.74 | Director | Sell | 1,270 | $27.67 | $35,143.31 | -1.0% | -20.7% | -21.9% |